Inhibrx Biosciences(INBX.US)

Last Updated 19:00:00 ET
longbridge loading

Stifel Nicolaus Sticks to Their Buy Rating for Inhibrx Biosciences Inc (INBX)

Tip Ranks·
US
INBX
+0.51%
US
PBE
+0.35%
US
SBIO
+1.84%
Tip Ranks·
US
INBX
+0.51%
US
PBE
+0.35%
US
SBIO
+1.84%

Inhibrx Reports First Quarter 2026 Financial Results | INBX Stock News

StockTitan·
US
INBX
+0.51%
US
PBE
+0.35%
US
LABU
+2.48%
StockTitan·
US
INBX
+0.51%
US
PBE
+0.35%
US
LABU
+2.48%

Top 10 US Stock Losers (5.12)

Top Gainers&Losers·
US
PSIX
+7.12%
US
GTM
-2.72%
US
DXYZ
+26.87%
Top Gainers&Losers·
US
PSIX
+7.12%
US
GTM
-2.72%
US
DXYZ
+26.87%

Inhibrx announces positive interim results from HexAgon trial

WorldPharmaceuticals·
US
INBX
+0.51%
US
BIB
+1.41%
US
XBI
+0.81%
WorldPharmaceuticals·
US
INBX
+0.51%
US
BIB
+1.41%
US
XBI
+0.81%

Inhibrx Biosciences’ INBRX-106 Combo Tops KEYTRUDA Alone in Phase 2 Cancer Study

Market Beat·
US
INBX
+0.51%
US
MRK
+2.55%
US
PBE
+0.35%
Market Beat·
US
INBX
+0.51%
US
MRK
+2.55%
US
PBE
+0.35%

Inhibrx Reports Interim Phase 2 Data for INBRX-106 in First-Line HNSCC; Initial Results Demonstrate Potential Costimulatory Benefit Over PD-1 Monotherapy | INBX Stock News

StockTitan·
US
INBX
+0.51%
US
BBH
+0.64%
US
LABU
+2.48%
StockTitan·
US
INBX
+0.51%
US
BBH
+0.64%
US
LABU
+2.48%
© 2026 Longbridge｜Disclaimer